Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko(AbbVie (United States)), Clarissa G. Jakob(AbbVie (United States)), Rohinton Edalji(AbbVie (United States)), Wei Qiu(AbbVie (United States)), Debra Montgomery(AbbVie (United States)), Enrico L. DiGiammarino(AbbVie (United States)), T. Matt Hansen(AbbVie (United States)), Roberto M. Risi(AbbVie (United States)), Robin R. Frey(AbbVie (United States)), Vlasios Manaves(AbbVie (United States)), Bailin Shaw(AbbVie (United States)), Mikkel A. Algire(AbbVie (United States)), Paul Hessler(AbbVie (United States)), Lloyd T. Lam(AbbVie (United States)), Tamar Uziel(AbbVie (United States)), Emily J. Faivre(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Ruth L. Martin(AbbVie (United States)), Maricel Torrent(AbbVie (United States)), Gary G. Chiang(Fate Therapeutics (United States)), Kannan R. Karukurichi, J. William Langston(Faraday Technology (United States)), Brian T. Weinert(University of Copenhagen), Chunaram Choudhary(Novo Nordisk Foundation), Peter de Vries, Arthur F. Kluge, Michael A. Patane(IIT@MIT), John H. Van Drie, Ce Wang(Novartis (China)), David McElligott, Ed Kesicki, Ronen Marmorstein(University of Pennsylvania), Chaohong Sun(AbbVie (United States)), Philip A. Cole(Johns Hopkins University), Saul H. Rosenberg(AbbVie (United States)), Michael R. Michaelides(AbbVie (United States)), Albert Lai(AbbVie (United States)), Kenneth D. Bromberg(AbbVie (United States))
Nature
September 26, 2017
10.1038/nature24028
Cited by 844Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis